Streetbeat News

Revenues

HTGC

Hercules Capital (NYSE:HTGC) has been the subject of diverse analyst opinions over the past three months, with 5 analysts offering ratings ranging from neutral to overweight. The average 12-month price target is $17.8, slightly down from the previous $17.83. Analysts from Wells Fargo and Piper Sandler have raised their price targets, while Piper Sandler also lowered one target. The company faces challenges with a -29.4% revenue decline as of September 30, 2023, but maintains a high net margin of 54.32%. Its ROE and ROA are below industry averages, and it has a high debt-to-equity ratio of 0.99.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 8:00 pm

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) has been evaluated by 14 analysts over the last three months, with diverse opinions ranging from bullish to bearish. The average 12-month price target for REGN is $963.57, with a high of $1076.00 and a low of $800.00, marking a 6.73% increase from the previous target of $902.83. Analysts have made various rating actions, including maintaining, raising, and lowering their stances and price targets. Regeneron is involved in developing treatments for diseases and has several marketed products. The company's financial performance shows a revenue growth of 14.53%, a high net margin of 29.97%, an ROE of 4.12%, an ROA of 3.21%, and a low debt-to-equity ratio of 0.11.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 8:00 pm

FSR

GOEV

LCID

RIVN

TSLA

VLCN

Shares of electric vehicle (EV) stocks are experiencing an uptick following a report by CleanTechnica that indicated a 29% increase in Q4 sales of pure electric vehicles.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 7:54 pm

RXST

Over the past three months, 8 analysts have provided ratings for RxSight (NASDAQ:RXST), with sentiments ranging from bullish to bearish. The average 12-month price target for RXST is $42.38, with a high of $54.00 and a low of $30.00, marking a 3.37% increase from the previous target of $41.00. Analysts from firms like Oppenheimer, Needham, Wells Fargo, Stifel, and Morgan Stanley have updated their ratings and price targets, reflecting their views on the company's market performance. RxSight, a medical technology company, has shown a revenue growth of 75.97% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -55.93%, ROE of -7.79%, and ROA of -6.58%. The company has a low debt-to-equity ratio of 0.02.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 7:00 pm

NSANY

Nissan has announced plans to manufacture lithium-ion batteries using lower-cost materials, aiming to install them in electric vehicles (EVs) sold in emerging markets by 2026. This move is part of Nissan's strategy to make EVs more affordable and accessible in these regions, potentially increasing the company's market share in the growing EV sector.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 6:33 pm

SIRI

Smartless Podcast Group has reportedly signed a deal worth $100 million with SiriusXM. This deal could potentially enhance content offerings and attract more subscribers to SiriusXM's platform.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 6:19 pm

LLY

NVO

Eli Lilly (LLY) is in talks with the German government to allow public health coverage for weight-loss treatments, following EU approval for its drug Mounjaro. The company plans to invest €2 billion in a German production plant. A study showed Mounjaro is more effective than Novo Nordisk's (NVO) Ozempic for weight loss. LLY shares rose 0.59%.

Portfolio Pulse from Vandana Singh

January 29, 2024 | 6:14 pm

MUR

Analysts have mixed views on Murphy Oil (NYSE:MUR), with recent ratings ranging from bullish to bearish. The average 12-month price target is $50.17, a slight decrease from the previous $51.20. Analysts from UBS, Piper Sandler, Keybanc, and Truist Securities have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Murphy Oil, an independent oil and gas company, reported a revenue decline of -11.69% as of December 31, 2023, and faces challenges in profitability and asset utilization, with a net margin of 13.81%, ROE of 2.17%, and ROA of 1.18%. The company's debt-to-equity ratio is below the industry average at 0.39.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 6:00 pm

AXP

Analysts have recently updated their ratings and price targets for American Express (NYSE:AXP), with 11 analysts offering a range of opinions. The average 12-month price target is now $198.27, up from the previous $189.00. Analysts from firms like RBC Capital, UBS, and BMO Capital have raised their price targets, while others have announced new ratings. American Express has shown strong financial performance with a 13.57% revenue growth rate, a net margin of 15.76%, an ROE of 8.95%, an ROA of 0.98%, and a debt-to-equity ratio of 1.76.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 6:00 pm

AHCO

AdaptHealth (NASDAQ:AHCO) has received mixed analyst ratings over the past three months, with 2 bullish, 1 somewhat bullish, and 1 somewhat bearish. The average 12-month price target is now $9.88, down from $14.00, with a high estimate of $13.00 and a low of $6.50. Analysts from UBS, RBC Capital, B of A Securities, and Truist Securities have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. AdaptHealth's financials show a market cap below industry benchmarks, a revenue growth of 4.67%, a net margin of -77.8%, an ROE of -23.21%, an ROA of -9.15%, and a debt-to-equity ratio of 1.33.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 6:00 pm